Search Clinical Trials in the European Union

Duration
Visits
Efficacy phase (II)
Intake methods
Benefits
Drugs
Locations
Clinical Specialty
341-360 of 1,738 trials

Spinal Muscular Atrophy: Risdiplam Study for Infants

We are investigating how the medication risdiplam works and its safety in infants with spinal muscular atrophy. This study aims to provide important insights into its use for this condition.

Spinal Muscular Atrophy1-2 yearsEfficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementNeurologyPediatrics

Kidney Cancer: New Treatment Study

We are investigating a new treatment option for individuals diagnosed with kidney cancer. The goal is to see if this treatment can improve outcomes compared to standard care.

Metastatic Renal Cell Carcinoma with End-Stage Renal Disease>2 yearsSafety phase (I)Efficacy phase (II)Oncology

Posaconazole for Young Children with Fungal Infections

We are studying how well Posaconazole works and its safety in children under 2 years old with invasive fungal infections. This research will help us understand its effects compared to older patients.

Fungal Infection3-6 monthsEfficacy phase (II)6-10 visitsNo PlaceboStandard MedicinesInfectious DiseasesPediatrics

Trastuzumab Deruxtecan (T-DXd) for Unresectable or Metastatic HER2-low Breast Cancer

We are studying the effects of T-DXd in patients with hormone receptor-negative and hormone receptor-positive HER2-low breast cancer. The goal is to see if it can improve treatment outcomes compared to current options.

Advanced Breast Cancer>2 yearsEfficacy phase (II)No PlaceboInvestigational MedicinesOncology

Richter's Syndrome: M-CHOP with Mosunetuzumab

We are studying a new treatment combining mosunetuzumab with CHOP for patients with Richter's Syndrome who have not had therapy before. The aim is to evaluate its effectiveness and safety.

Richter's Syndrome1-2 yearsEfficacy phase (II)No PlaceboStandard MedicinesHematologyOncology

B-Cell Non-Hodgkin’s Lymphoma: Glofitamab and Obinutuzumab Study

We are studying the safety and effectiveness of Glofitamab alone and with Obinutuzumab in patients with relapsed or refractory B-cell Non-Hodgkin’s Lymphoma. This trial aims to find the best dose and understand how these treatments work together.

Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma6-12 monthsSafety phase (I)Efficacy phase (II)Post-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementOncology

Lupus Treatment: BIIB059 Study

We are testing a new medication, BIIB059, for people with active subacute or chronic cutaneous lupus who haven't responded to standard treatments. The study aims to see if it can reduce skin disease activity and improve overall safety.

Skin Lupus1-2 yearsEfficacy phase (II)Confirmation phase (III)>20 visitsInvestigational MedicinesCost ReimbursementPartially RemoteDermatologyRheumatology

Metastatic Neuroendocrine Prostate Cancer: Targeted Radioligand Therapy

We are exploring a new targeted treatment for patients with metastatic neuroendocrine prostate cancer. This study aims to assess its safety and effectiveness compared to existing therapies.

Metastatic Neuroendocrine Prostate Cancer>2 yearsSafety phase (I)Efficacy phase (II)Oncology

Non-Small-Cell Lung Cancer: Amivantamab Treatment Study

We are studying the effects of a new antibody treatment, amivantamab, alone and with chemotherapy for patients with early-stage lung cancer. This research aims to see if it helps before surgery and how it affects tumor characteristics.

Non-Small Cell Lung Cancer (NSCLC) with EGFR Mutation>2 yearsEfficacy phase (II)6-10 visitsNo PlaceboStandard MedicinesOncology

Epithelial Ovarian Cancer: Sentinel Node Detection Study

We are testing two tracers to see if they improve the detection of sentinel lymph nodes in patients with early-stage epithelial ovarian cancer. This may help in better understanding the cancer's spread and improving surgical outcomes.

Ovarian Epithelial Cancer>2 yearsEfficacy phase (II)Standard MedicinesGynecology and ObstetricsOncology

Ulcerative Colitis: Lutikizumab Treatment Study

We are assessing the safety and effectiveness of lutikizumab in adults with active ulcerative colitis. This study compares it to an existing treatment to see if it offers better results.

Ulcerative Colitis1-2 yearsEfficacy phase (II)>20 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteGastroenterologyInternal Medicine

Advanced Non-Small Cell Lung Cancer: OSIBOOST 2 Study

We are testing a modified dosing strategy of osimertinib, with or without a booster drug, for patients with advanced EGFR mutated NSCLC. This study aims to improve treatment cost-effectiveness and reduce side effects while maintaining effectiveness.

Non-Small Cell Lung Cancer with an EGFR Mutation≤3 monthsEfficacy phase (II)≤5 visitsNo PlaceboStandard MedicinesCost ReimbursementOncologyPulmonology

Fosigotifator for Vanishing White Matter Disease

We are exploring the safety and tolerability of Fosigotifator in adults and children with Vanishing White Matter Disease. This study aims to understand how the body handles this new treatment.

Vanishing White Matter Disease>2 yearsSafety phase (I)Efficacy phase (II)11-15 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesPartially RemoteNeurology

HER2-Positive Biliary Tract Cancer: GemCis with Trastuzumab and Pembrolizumab

We are studying a combination of treatments for people with HER2-positive biliary tract cancer to see if it improves response rates and overall survival. This trial aims to assess both the effectiveness and safety of the treatment.

Cholangiocarcinoma and Gallbladder Carcinoma>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesOncology

Head Trauma: Safety of Inhaled Isoflurane

We are evaluating the safety of using inhaled Isoflurane for sedation in patients with head trauma. This study aims to ensure that this method is safe for these patients.

Head Trauma>2 yearsEfficacy phase (II)Internal MedicineNeurologyOtolaryngology

End-Stage Renal Disease: Rivaroxaban Dosing Study

We are studying different doses of rivaroxaban to find the safest option for patients on chronic hemodialysis. The trial will also look at the risk of bleeding with each dose.

Chronic Hemodialysis≤3 monthsEfficacy phase (II)No PlaceboStandard MedicinesInternal MedicineNephrology

Tumor Treatment: Botensilimab and Balstilimab Study

We are studying a new combination of immune therapies for patients with specific tumor types to see if it can reduce tumor size before surgery. This trial aims to improve treatment effectiveness and safety.

dMMR Tumors≤3 monthsEfficacy phase (II)No PlaceboInvestigational MedicinesInternal MedicineOncology

Early Breast Cancer: Elacestrant and Ribociclib Study

We are testing a new treatment combination of elacestrant and ribociclib for patients with hormone-sensitive early breast cancer. The goal is to see if this combination works better than standard therapies before surgery.

Hormone Receptor Positive HER2 Negative Breast Cancer6-12 monthsEfficacy phase (II)11-15 visitsNo PlaceboStandard MedicinesGynecology and ObstetricsOncology

Hereditary Angioedema: PHA-022121 Treatment Study

We are testing the safety of a new oral medication for treating acute angioedema attacks in patients with hereditary angioedema. The study will also evaluate how well it relieves symptoms during these attacks.

Hereditary AngioedemaEfficacy phase (II)Confirmation phase (III)Post-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteAllergologyInternal Medicine

Lung Cancer Treatment: Livmoniplimab and Budigalimab

We are studying a new combination of drugs for adults with untreated metastatic non-squamous non-small cell lung cancer. The goal is to see if this combination works better than a standard treatment with pembrolizumab and chemotherapy.

Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer>2 yearsEfficacy phase (II)Confirmation phase (III)>20 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteOncology